SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a 2017 Top Workplace by The San Diego Union-Tribune. Top Workplaces lists are based solely on the results of an annual employee survey administered by Energage, LLC, a leading, independent research firm. Surveys measure several aspects of workplace culture, including alignment, execution, and connection. For 2017, among the companies with fewer than 100 employees, Cidara ranked among the top 10 best places to work in the San Diego Metro Area and is the only biotech or public company featured in the top 10.
“We are honored to receive this recognition, which reflects our commitment to creating a positive and collaborative work environment where employees feel valued and fulfilled,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are fortunate to have an incredibly experienced team, which recognizes that this type of environment is not only personally beneficial to our employees, but encourages new ideas and different perspectives that foster innovation and, accordingly, lead to scientific and corporate success.”
As part of its goal to provide a well-rounded employee experience, Cidara rewards employees for individual performance as well as their contributions toward the company’s strategic goals. Additionally, to drive a strong corporate culture, Cidara has established multiple recognition programs to recognize and reward employees who demonstrate behaviors that support a common set of core principles and organizational values.
The San Diego Union-Tribune published the complete list of 2017 Top Workplaces on Sunday, November 12. The list of winners is available at: http://www.topworkplaces.com/frontend.php/regional-list/list/sandiego.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly called CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201 and back-up molecules. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Sam Brown Inc.